Synergistic Tissue Kallikrein 1 Systems for Personalized Ischemic Condition Treatment

This inventive concept integrates dosage forms of tissue kallikrein 1 with distinct technologies such as AI, IoT, blockchain, and nanomaterials to create a more powerful system for treating ischemic conditions, enabling personalized dosage optimization, real-time monitoring, and secure data storage.

The original patent disclosed dosage forms of tissue kallikrein 1 for treating ischemic conditions, but it had limitations in terms of personalized treatment and data management. This inventive concept addresses these limitations by combining the patented dosage forms with advanced technologies to create a more effective and efficient system.

The system comprises a dosage form of tissue kallikrein 1, an artificial intelligence module for personalized dosage optimization, IoT-enabled sensors for real-time monitoring, a blockchain-based decentralized data storage module for secure storage and sharing of medical records, and a nanomaterial-based sensor array for wearable devices. The AI module analyzes patient data and optimizes dosage, while the IoT sensors track treatment efficacy and the blockchain module ensures secure data storage. The wearable device enables real-time monitoring, and the nanomaterial-based sensor array enhances sensitivity and accuracy.

The new claims introduce the synergistic combination of dosage forms of tissue kallikrein 1 with AI, IoT, blockchain, and nanomaterials, which is not obvious from the original patent. The inventive step lies in the integration of these distinct technologies to create a more powerful system for treating ischemic conditions.

Alternative embodiments may include integrating the dosage forms with other AI algorithms, using different IoT sensors or blockchain platforms, or incorporating other nanomaterials or wearable devices. Variations may include using the system for treating other conditions, such as cancer or inflammatory diseases.

This inventive concept has significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine, telemedicine, and digital health. The target market includes hospitals, clinics, and research institutions, as well as patients and healthcare providers.